OTUD6B-AS1 Might Be a Novel Regulator of Apoptosis in Systemic Sclerosis by Takata, Miki et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
OTUD6B-AS1 Might Be a Novel Regulator of Apoptosis in Systemic
Sclerosis
Takata, Miki; Pachera, Elena; Frank-Bertoncelj, Mojca; Kozlova, Anastasiia; Jüngel, Astrid; Whitfield,
Michael L; Assassi, Shervin; Calcagni, Maurizio; de Vries-Bouwstra, Jeska; Huizinga, Tom W;
Kurreeman, Fina; Kania, Gabriela; Distler, Oliver
Abstract: Antisense long non-coding RNAs (AS lncRNAs) have increasingly been recognized as im-
portant regulators of gene expression and they have been found to play key roles in several diseases.
However, very little is known about the role of AS lncRNAs in fibrotic diseases such as systemic scle-
rosis (SSc). Our recent screening experiments by RNA sequencing showed that ovarian tumor domain
containing 6B antisense RNA1 (OTUD6B-AS1) and its sense gene OTUD6B were significantly down-
regulated in SSc skin biopsies. Therefore, we aimed to identify key regulators of OTUD6B-AS1 and to
analyze the functional relevance of OTUD6B-AS1 in SSc. OTUD6B-AS1 and OTUD6B expression in
SSc and healthy control (HC) dermal fibroblasts (Fb) after stimulation with transforming growth factor-￿
(TGF￿), Interleukin (IL)-4, IL-13, and platelet-derived growth factor (PDGF) was analyzed by qPCR.
To identify the functional role of OTUD6B-AS1, dermal Fb or human pulmonary artery smooth muscle
cells (HPASMC) were transfected with a locked nucleic acid antisense oligonucleotide (ASO) targeting
OTUD6B-AS1. Proliferation was measured by BrdU and real-time proliferation assay. Apoptosis was
measured by Caspase 3/7 assay and Western blot for cleaved caspase 3. While no difference was recorded
at the basal level between HC and SSc dermal Fb, the expression of OTUD6B-AS1 and OTUD6B was
significantly downregulated in both SSc and HC dermal Fb after PDGF stimulation in a time-dependent
manner. Only mild and inconsistent effects were observed with TGF￿, IL-4, and IL-13. OTUD6B-AS1
knockdown in Fb and HPASMC did not affect extracellular matrix or pro-fibrotic/proinflammatory cy-
tokine production. However, OTUD6B-AS1 knockdown significantly increased Cyclin D1 expression at
the mRNA and protein level. Moreover, silencing of OTUD6B-AS1 significantly reduced proliferation
and suppressed apoptosis in both dermal Fb and HPASMC. OTUD6B-AS1 knockdown did not affect
OTUD6B expression at the mRNA level and protein level. Our data suggest that OTUD6B-AS1 regu-
lates proliferation and apoptosis via cyclin D1 expression in a sense gene independent manner. This is
the first report investigating the function of OTUD6B-AS1. Our data shed light on a novel apoptosis
resistance mechanism in Fb and vascular smooth muscle cells that might be relevant for pathogenesis of
SSc.
DOI: https://doi.org/10.3389/fimmu.2019.01100
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-171467
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Takata, Miki; Pachera, Elena; Frank-Bertoncelj, Mojca; Kozlova, Anastasiia; Jüngel, Astrid; Whitfield,
Michael L; Assassi, Shervin; Calcagni, Maurizio; de Vries-Bouwstra, Jeska; Huizinga, TomW; Kurreeman,
Fina; Kania, Gabriela; Distler, Oliver (2019). OTUD6B-AS1 Might Be a Novel Regulator of Apoptosis
in Systemic Sclerosis. Frontiers in Immunology, 10:1100.
DOI: https://doi.org/10.3389/fimmu.2019.01100
2
ORIGINAL RESEARCH
published: 17 May 2019
doi: 10.3389/fimmu.2019.01100
Frontiers in Immunology | www.frontiersin.org 1 May 2019 | Volume 10 | Article 1100
Edited by:
Jérôme Avouac,
Université Paris Descartes, France
Reviewed by:
Xinhua Yu,
Forschungszentrum Borstel
(LG), Germany
Amelie Servettaz,
Centre Hospitalier Universitaire de
Reims, France
*Correspondence:
Oliver Distler
Oliver.Distler@usz.ch
†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Immunological Tolerance and
Regulation,
a section of the journal
Frontiers in Immunology
Received: 30 October 2018
Accepted: 30 April 2019
Published: 17 May 2019
Citation:
Takata M, Pachera E,
Frank-Bertoncelj M, Kozlova A,
Jüngel A, Whitfield ML, Assassi S,
Calcagni M, Vries-Bouwstra Jd,
Huizinga TW, Kurreeman F, Kania G
and Distler O (2019) OTUD6B-AS1
Might Be a Novel Regulator of
Apoptosis in Systemic Sclerosis.
Front. Immunol. 10:1100.
doi: 10.3389/fimmu.2019.01100
OTUD6B-AS1 Might Be a Novel
Regulator of Apoptosis in Systemic
Sclerosis
Miki Takata 1†, Elena Pachera 1†, Mojca Frank-Bertoncelj 1, Anastasiia Kozlova 1,
Astrid Jüngel 1, Michael L. Whitfield 2, Shervin Assassi 3, Maurizio Calcagni 4,
Jeska de Vries-Bouwstra 5, Tom W. Huizinga 5, Fina Kurreeman 5, Gabriela Kania 1 and
Oliver Distler 1*
1Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zürich, Zurich, Switzerland,
2Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, United States,
3Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston,
McGovern Medical School, Houston, TX, United States, 4Department of Plastic Surgery and Hand Surgery, University
Hospital Zürich, Zurich, Switzerland, 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Antisense long non-coding RNAs (AS lncRNAs) have increasingly been recognized
as important regulators of gene expression and they have been found to play
key roles in several diseases. However, very little is known about the role of AS
lncRNAs in fibrotic diseases such as systemic sclerosis (SSc). Our recent screening
experiments by RNA sequencing showed that ovarian tumor domain containing
6B antisense RNA1 (OTUD6B-AS1) and its sense gene OTUD6B were significantly
downregulated in SSc skin biopsies. Therefore, we aimed to identify key regulators
of OTUD6B-AS1 and to analyze the functional relevance of OTUD6B-AS1 in SSc.
OTUD6B-AS1 and OTUD6B expression in SSc and healthy control (HC) dermal
fibroblasts (Fb) after stimulation with transforming growth factor-β (TGFβ), Interleukin
(IL)-4, IL-13, and platelet-derived growth factor (PDGF) was analyzed by qPCR. To
identify the functional role of OTUD6B-AS1, dermal Fb or human pulmonary artery
smooth muscle cells (HPASMC) were transfected with a locked nucleic acid antisense
oligonucleotide (ASO) targeting OTUD6B-AS1. Proliferation was measured by BrdU
and real-time proliferation assay. Apoptosis was measured by Caspase 3/7 assay
and Western blot for cleaved caspase 3. While no difference was recorded at the
basal level between HC and SSc dermal Fb, the expression of OTUD6B-AS1 and
OTUD6B was significantly downregulated in both SSc and HC dermal Fb after PDGF
stimulation in a time-dependent manner. Only mild and inconsistent effects were
observed with TGFβ, IL-4, and IL-13. OTUD6B-AS1 knockdown in Fb and HPASMC
did not affect extracellular matrix or pro-fibrotic/proinflammatory cytokine production.
However, OTUD6B-AS1 knockdown significantly increased Cyclin D1 expression at
the mRNA and protein level. Moreover, silencing of OTUD6B-AS1 significantly reduced
proliferation and suppressed apoptosis in both dermal Fb and HPASMC. OTUD6B-AS1
knockdown did not affect OTUD6B expression at the mRNA level and protein
level. Our data suggest that OTUD6B-AS1 regulates proliferation and apoptosis via
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cyclin D1 expression in a sense gene independent manner. This is the first report
investigating the function of OTUD6B-AS1. Our data shed light on a novel apoptosis
resistance mechanism in Fb and vascular smooth muscle cells that might be relevant for
pathogenesis of SSc.
Keywords: systemic sclerosis, ovarian tumor domain containing 6B-antisense RNA1 (OTUD6B-AS1), antisense
long non-coding RNA (AS lncRNA), cyclin D1, proliferation, apoptosis, dermal fibroblasts, human pulmonary artery
smooth muscle cells
INTRODUCTION
Systemic sclerosis (SSc) is an autoimmune disease characterized
by immune abnormalities, microvascular dysfunction, and
fibrosis in the skin and multiple internal organs. Patients are
sub-classified into limited cutaneous systemic sclerosis (lcSSc)
and diffuse cutaneous systemic sclerosis (dcSSc), based on
the extent of skin involvement. Fibrosis in multiple internal
organs is an important contributor to the high mortality in
SSc. Upregulation of profibrotic cytokines such as PDGF
and TGFβ and their respective signaling pathways is a
key feature of SSc (1, 2). Microvascular manifestations
include loss of capillaries and vessel wall thickening of
small arteries leading to reduced perfusion and hypoxia.
Major clinical manifestations of the microvasculopathy are
digital ulcers and pulmonary arterial hypertension (PAH).
PAH is another major contributor to death in SSc patients.
However, the molecular pathogenesis of SSc leading to
these manifestations is still not fully understood and there
is no registered approved anti-fibrotic therapy available to
date (3–5).
Long non-coding RNAs (lncRNAs) represent a class of
transcripts longer than 200 nucleotides that are not translated
into proteins. LncRNAs have been classified by their genomic
location into intergenic lncRNA, intronic lncRNA, bidirectional
lncRNA, enhancer lncRNA, sense lncRNA, and antisense (AS)
lncRNA (6). AS lncRNAs are transcribed from the opposite
strand of protein-coding genes and overlap one or several
exons and introns with the sense gene. High-throughput RNA
sequencing analysis showed that for most AS lncRNAs the
expression is about 10-fold lower than for their coding gene
(7, 8). Moreover, the expression of AS lncRNAs is more
tissue specific than those of protein coding genes (8–10). In
recent years, AS lncRNAs have increasingly been recognized as
important regulators of their sense gene expression. However,
some AS lncRNAs can exert their biologic effects independently
of the sense gene. For example, NKX2-1-AS1 is an AS lncRNA
that has been linked to human lung carcinoma. NKX2-1-AS1
regulates CD274, the gene encoding the Programmed Death-
Ligand 1 (PD-L1), and cell-cell interaction genes, but not
the adjacent protein-coding gene NKX2-1 (11). In general,
AS lncRNAs can function either in cis or in trans. In
cis, lncRNAs regulate the expression of transcription sites
on the same chromosome. In trans, lncRNAs regulate the
gene expression on other chromosomes (9, 12). AS lncRNAs
affect almost all stages of gene expression processes via
pre-transcriptional, co-transcriptional, or post-transcriptional
mechanisms (12–14).
Recently, a variety of studies have reported that AS
lncRNAs play key roles in the pathogenesis of different diseases
including cancers (15–17), cardiac vascular diseases (6, 18),
kidney diseases (18), and central nervous system diseases (19).
However, only very few AS lncRNAs have been linked to
SSc and fibrosis (20, 21). Previous RNA sequencing analysis
of SSc and healthy control (HC) skin biopsies performed by
our groups revealed 676 differentially expressed non-coding
genes, 38% of these non-coding genes were classified as
antisense genes. The differentially expressed antisense genes
included ovarian tumor domain containing 6B (OTUD6B)-
AS1 (22).
The sense gene, OTUD6B, encodes for a deubiquitinating
enzyme. Deubiquitinating enzymes are classified into five
families based on the architecture of their catalytic domains.
OTUD6B belongs to the ovarian tumor proteases (OTUs) family.
Additional families are ubiquitin specific proteases (USPs),
ubiquitin COOH-terminal hydrolases (UCHs), Josephins, and
the JAB1/MPN/MOV34 family (JAMMs) (23). It has been
shown that deubiquitinating enzymes have crucial roles in
many biological processes, including cell cycle regulation,
apoptosis, and DNA repair. In particular, they can regulate
specific molecular pathways such as Wnt/β-catenin and NFκB
signaling (24).
Little is known about the function of OTUD6B. OTUD6B
has been suggested to be involved in cell cycle regulation in
B lymphocytes after prolonged cytokine stimulation and in
DNA synthesis in non-small cell lung cancer cells (25, 26).
Moreover, defective OTUD6B function has been associated with
cognitive dysfunction and dysmorphic features in development
(27). There is no information available about the function of the
antisense lncRNA, OTUD6B-AS1. OTUD6B-AS1 is transcribed
from the opposite strand of the OTUD6B gene, which is located
on chromosome 8 in head-to-head orientation to OTUD6B-
AS1 (Figure 1A).
Here, we analyzed the differential expression of OTUD6B-
AS1 in SSc skin biopsies, identified pro-inflammatory and pro-
fibrotic regulators of OTUD6B-AS1 expression, and defined
the functional roles of OTUD6B-AS1 in the pathophysiology
of SSc. In particular, we focused on OTUD6B-AS1 role in
proliferation and apoptosis of human dermal fibroblasts and
human pulmonary artery smooth muscle cells (HPASMC),
which represent the two major cellular players in fibrosis and
vasculopathy of SSc.
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FIGURE 1 | Genomic localization and basal expression in skin of OTUD6B-AS1 and OTUD6B. (A) OTUD6B-AS1 and OTUD6B are located on chromosome 8 and
oriented head-to-head (GENCODE v27). (B) In the Leiden cohort, OTUD6B-AS1, and OTUD6B expression was analyzed in healthy control (HC), non-involved and
involved skin of systemic sclerosis patients (SSc) using next generation sequencing [HC: n = 6, SSc (non-involved): n = 4, SSc (involved): n = 10, (22)]. (C) In the
Zurich cohort, OTUD6B-AS1, and OTUD6B expression was measured in HC and non-involved SSc patients skin by qPCR (HC: n = 5, SSc (non-involved): n = 6).
Expression level was normalized using RPLP0. (C). Data are shown as single values and mean. Statistical analysis was performed by unpaired t-test. N.S,
not significant.
METHODS
Cell Culture
Skin biopsies were obtained from the forearm of SSc patients at
the Department of Rheumatology, University Hospital Zurich,
Switzerland or at the Department of Internal Medicine, Division
of Rheumatology, University of Texas Health Science Center,
Houston, USA. All patients fulfilled the American College of
Rheumatology (ACR)/European League Against Rheumatism
(EULAR) 2013 criteria for SSc. Healthy donors were obtained
from the Department of Plastic Surgery and Hand Surgery
of the University Hospital Zurich. Donors characteristics are
listed in Table 1. Patients and healthy subjects from the Leiden
and Dartmouth cohort have been described elsewhere (22). In
general, skin areas with clinically detectable fibrotic changes
are referred to as “involved skin,” and skin areas without
clinically detectable fibrotic changes are referred to as “non-
involved skin.” This study was carried out in accordance
with the recommendations of World Medical Association
Declaration of Helsinki, ICH-GCP guidelines or ISO 14155.
The study was approved by the Ethics Committee of the
Canton of Zurich (approved ethical applications KEK-ZH 515,
PB-2016-02014, and KEK-Nr. 2018-01873). All subjects gave
written informed consent in accordance with the Declaration
of Helsinki.
Human dermal fibroblasts (Fb) were isolated from SSc and
site-matched HC skin biopsies by outgrowth culture. Dermal
Fb were maintained in Dulbecco’s modified eagle’s medium
(DMEM, Sigma) supplemented with 10% fetal bovine serum
(FBS), 50 units/ml of penicillin, 50µg/ml of streptomycin and 2
µl/ml 2-mercaptoethanol. Fb from passages 4 to 11 were used for
all experiments.
Human pulmonary artery smooth muscle cells (HPASMC)
were purchased from ScienCell and maintained in smooth
muscle cell medium (SMCM, ScienCell) supplemented with 1%
FBS, 100 units/ml of penicillin, 100µg/ml of streptomycin, and
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TABLE 1 | Characteristics of systemic sclerosis (SSc) patients and healthy control (HC) donors in the Zurich cohort.
Donor Gender Site of biopsy Disease subtype Disease duration
(years)
mRSS Fibrosis at the
site of biopsy
Skin biopsy
expression analysis
PDGF stimulation/
functional assays
SSc 1 Female Forearm Diffuse 10.16 4 No x x
SSc 2 Male Forearm Diffuse 1.32 16 Yes x x
SSc 3 Female Forearm Diffuse 9.16 6 No x
SSc 4 Male Forearm Diffuse 0.72 n.a. n.a. x
SSc 5 Male Forearm Limited n.a. 0 No x
SSc 6 Female Forearm Limited 6.0 0 No x
SSc 7 Female Forearm Limited n.a. 0 No x x
SSc 8 Female Forearm Limited n.a. 6 No x
SSc 9 Female Forearm Limited n.a. 3 No x
HC 1 Female Abdomen x
HC 2 Female Breast x
HC 3 Female Hernia surgery x
HC 4 Male Forearm x
HC 5 Male Forearm x
HC 6 Male Forearm x x
HC 7 Male Forearm x x
HC 8 Female Breast x
HC 9 Male Forearm x
HC 10 Male Forearm x
HC 11 Female Forearm x
HC 12 Female Forearm x
HC 13 Female Forearm x
HC 14 Male Forearm x
Skin biopsies were obtained from patients fulfilling the American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) 2013 criteria. The disease subset
was determined according to the criteria proposed by LeRoy et al. (28). Disease duration was measured from the onset of the first non-Raynaud symptoms attributable to SSc. n.a,
not available.
smoothmuscle cell growth supplement (all, ScienCell). HPASMC
from passages 4 to 9 were used in all experiments.
Dermal Fb and HPASMC were cultured at 37◦C in a
humidified 5% CO2-containing atmosphere. Dermal Fb and
HPASMC were stimulated with transforming growth factor-
β (TGFβ; 10 ng/ml, PeproTech), Interleukin (IL)-4 (10 ng/ml,
ImmunoTools), IL-13 (10 ng/ml, ImmunoTools), and platelet-
derived growth factor (PDGF; 20 ng/ml, PeproTech) for 6, 24, 48,
and 72 h.
Cell Fractionation
To detect the localization of lncRNA OTUD6B-AS1, dermal
Fb were fractionated as previously described (29). Cells were
trypsinized, lysed with hypotonic lysis buffer (10mM Tris-
HCl pH 7.5, 10mM NaCl, 3mM MgCl2, 0.3% NP-40 and
10% glycerol) supplemented with RNase inhibitor (SUPERase-
In, Thermo Fisher Scientific) and incubated on ice for
20min. Cells were then centrifuged at 10,00 g at 4◦C for
3min. Supernatant (cytoplasmic fraction) was taken and RNA
precipitated in 150mM ethanol sodium acetate at −20◦C
for 1 h. Cell pellets (nuclear fraction) were washed with
hypotonic lysis buffer and centrifuged at 200 g at 4◦C for
2min. Precipitated cytoplasmic RNA was pelleted, washed in
ice-cold 70% ethanol and centrifuged at 17,000 g at 4◦C for
5min. Finally, Trizol was added to both fractions and RNA
was extracted.
Transient Transfection of Dermal Fb
and HPASMC
To identify the function of the lncRNA OTUD6B-AS1,
HC Fb, or HPASMC were transfected with locked nucleic
acid antisense oligonucleotide (ASO, QIAGEN) targeting
OTUD6B-AS1 (k.d.: 5′- GAATGAAATAGACGTT−3′,
k.d._2: 5′-TTCAGTAATTCGATT-3′, k.d._3: 5′-
GGACCAAAATCAAAGA-3′, final concentration of 25 nM
for dermal Fb and 50 nM for HPASMC) using a concentration
of 2 µl/ml Lipofectamine 2,000 transfection reagent according
to the manufacturer’s protocol (Thermo Fisher Scientific). Cells
were harvested for gene and protein expression analysis 24, 48,
72 h after transfection or prepared for functional assays.
RNA Isolation and cDNA Synthesis
Total RNA was extracted from cultured cells using the High
Pure RNA Isolation Kit (Roche) according to the manufacturer’s
instructions. RNA concentration of isolated RNA was assessed
using spectrophotometer (NanoDrop). For complementary DNA
(cDNA) synthesis, 200 ng of total RNA was reverse-transcribed
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using random hexamers and reverse transcriptase using the
Transcriptor First Strand cDNA Synthesis Kit (Roche).
RNA Sequencing and Quantitative
Real-Time PCR (qPCR) Analysis
RNA sequencing performed on the skin biopsies from Leiden
has been described recently (22). Total RNA extracted from skin
biopsies from Zurich as well as functional in vitro experiments
were analyzed by qPCR (Stratagene Mx3005P QPCR system,
Agilent Technologies) using SYBR GreenMaster Mix (Promega).
The expression of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and ribosomal protein lateral stalk subunit P0
(RPLP0) was used to normalize the obtained expression levels
for the gene of interest. Primer sequences are listed in the
(Supplementary Table 1). Specific amplification was verified
measuring dissociation curves. Differential gene expression was
calculated using the comparative threshold cycle method (11Ct
method) (30).
Western Blotting
Cells were lysed using ice-cold RIPA buffer (Sigma)
supplemented with phosphatase inhibitor cocktail (PhosSTOP,
Roche) and protease inhibitor cocktail (cOmplete ULTRA
Tablets, Roche). Insoluble material was removed by
centrifugation at 12,000 rpm, 20min at 4◦C. Whole cell
lysates were separated on 10 or 12% SDS polyacrylamide gel
electrophoresis (SDS-PAGE) and proteins were transferred
by electroblotting onto nitrocellulose membranes (Amersham
Protran, GE Healthcare). Membranes were blocked with
5% non-fat milk in Tris-buffered saline containing 0.1%
Tween20 (TBS-T) and incubated for 1 h. Western blots were
performed using rabbit anti OTUD6B antibody (Abcam,
#ab127714, 1:3,000), rabbit anti Cyclin D1 antibody (Cell
signaling, #2978, 1:1,000), rabbit anti Cyclin D2 antibody (Cell
signaling, #3741, 1:1,000), rabbit anti c-MYC antibody (Cell
signaling, #13987, 1:1,000), rabbit anti Caspase 3 antibody
(Cell signaling, #9662, 1:1,000) which detects both cleaved and
uncleaved forms of caspase 3, rabbit anti E2F1 antibody
(Abcam, #ab179445, 1:1,000), and rabbit anti GAPDH
antibody (Cell signaling, #2118, 1:10,000). Bands were detected
using goat anti rabbit secondary antibodies conjugated to
horseradish peroxidase (Abcam, #ab6721, 1:5000). Cyclin D1,
Cyclin D2, c-MYC, E2F1 expression was normalized to the
expression of GAPDH, and cleaved caspase 3 expression was
normalized to uncleaved caspase 3 expression. Calculation
of the relative expression of protein was performed using
ImageJ software.
BrdU Cell Proliferation ELISA
To quantify cell proliferation, dermal Fb, and HPASMC were
seeded in 96-well plates at a density of 2,000 cells per well and
transfected with the ASO negative control or ASO targeting
OTUD6B-AS1. Seventy-two hours after transfection, 5-bromo-
2′-deoxyuridine (BrdU) was added to each well and incubated for
four additional hours. Incorporated BrdU was detected using the
BrdU (colorimetric) cell proliferation ELISA kit (Roche/Sigma-
Aldrich) according to the manufacturer’s instructions.
Real-Time Monitoring of Proliferation
Real-time monitoring of cell proliferation was performed
using the xCelligence RTCA DP system (ACEA Biosciences).
Background impedance was measured 30min after adding 100
µl of culture medium to E-plates 16 PET (ACEA Biosciences).
Next, either 2,500 dermal Fb or 3,000 HPASMC per 100 µl of
culture medium per well were seeded. After 30min incubation
at room temperature, plates were placed into the xCelligence
system. The relative change in electrical impedance termed the
Cell Index (CI) was measured. Fb and HPASMCwere transfected
with negative control or ASO targeting OTUD6B-AS1 26 h or
50 h after seeding, respectively. CI was monitored every 5min
from 0 h to 13 h, every 15min from 13 h to 25 h and every 30min
from 25 h until CI reached plateau. CI was normalized at the
time of transfection for every experiment. The RTCA software
2.0 (ACEA Biosciences) was used to calculate the slope of the CI
curve as measure of cell proliferation.
Caspase 3/7 Assay
To measure caspase-3 and caspase-7 activities, dermal Fb, and
HPASMC were seeded in 96-well plates at a density of 2,000 cells
per well and transfected with either ASO negative control or ASO
targeting OTUD6B-AS1 (final concentration of 25 nM for dermal
Fb and 50 nM for HPASMC) as described above. To induce
caspase 3/7 activation, cells were treated with 1µM staurosporin
(STP) 16 h before starting the assay (31, 32). Forty-eight or
seventy-two hours after transfection, equal volumes of Caspase-
Glo R© 3/7 Reagent (Promega) were added into the cell culture
medium and incubated for additional 1.5 h at room temperature.
Luminescence as a measure of caspase 3/7 activity was recorded
by plate-reading luminometer (Synergy HT, BioTek).
Statistics
All data are presented as mean ± standard deviation (SD).
Paired samples were analyzed by two-tailed paired t-test, and
unpaired samples were analyzed by unpaired t-test. Comparison
of multiple groups was performed by one-way ANOVA with
Dunnett’s multiple comparisons test. P < 0.05 were considered
statistically significant. All statistic tests were performed with
GraphPad Prism version 7.0.
RESULTS
OTUD6B-AS1 and OTUD6B Expression Is
Downregulated in SSc Skin
RNA sequence analysis of 6 HC and 14 SSc patients skin biopsies
performed at the Leiden University Medical Center showed
that OTUD6B-AS1 expression was significantly downregulated
in SSc skin and this was the most differentially expressed AS
lncRNA. Moreover, the sense gene OTUD6B expression was
also significantly downregulated in SSc skin (22). Interestingly,
additional subanalysis showed that this downregulation in SSc
skin was mostly seen in skin biopsies from involved skin, while
non-involved skin did not show statistically significant changes
as compared to healthy controls (Figure 1B). In addition,
recently performed RNA sequencing analysis of additional
6 HC and 14 SSc biopsies performed at Geisel School of
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Medicine at Dartmouth, confirmed OTUD6B-AS1 as one of
the top downregulated AS lncRNAs (22). The expression of
OTUD6B-AS1 and OTUD6B was not changed in biopsies
from the Zurich cohort, which only consisted of non-involved
SSc skin biopsies as revealed by qPCR analysis (Figure 1C).
Together, these data from different cohorts indicate that the
expression of OTUD6B-AS1 and OTUD6B is downregulated in
skin biopsies from SSc patients, mostly in clinically involved,
fibrotic areas.
OTUD6B-AS1 and OTUD6B Expression in
Dermal Fb Is Tightly Regulated by PDGF
OTUD6B-AS1 and OTUD6B are strongly expressed in dermal
Fb as well as in other cells types present in the skin (22).
Therefore, we compared the expression levels of OTUD6B-AS1
and OTUD6B in dermal Fb. Under basal conditions, there was
no statistically significant difference between HC and SSc Fb
(Supplementary Figure 1).
Based on the expression in fibrotic areas in skin biopsies,
we hypothesized that immunomodulatory cytokines involved
in the pathophysiology of fibrosis might be important for the
downregulation of OTUD6B-AS1 and OTUD6B. We therefore
analyzed their time course response after stimulation with PDGF,
TGFβ, IL-4 and IL-13.
OTUD6B-AS1 expression in dermal Fb from SSc patients
was significantly downregulated after 24, 48, and 72 h of
PDGF stimulation. OTUD6B expression was significantly
upregulated after 6 h of PDGF stimulation, while after
longer stimulation, the expression levels decreased to become
significantly downregulated at 72 h (Figure 2A).
We also analyzed the time course response to PDGF of
OTUD6B-AS1 and OTUD6B in HC dermal Fb. In general,
the effects of PDGF on the expression of OTUD6B-AS1 and
OTUD6B in HC dermal Fb were similar to that observed in
SSc dermal Fb (Figure 2B). These data suggest that PDGF
strongly suppresses OTUD6B-AS1 and OTUD6B expression in
dermal Fb, reflecting the expression pattern observed in SSc
skin samples.
The effects after stimulation with other pro-fibrotic and pro-
inflammatory cytokines were overall less consistent. OTUD6B-
AS1 expression was slightly, but significantly upregulated after
72 h of TGFβ stimulation and significantly downregulated after
72 h of IL-4 stimulation. IL-4 slightly increased OTUD6B
expression after 48 h of stimulation. However, we could not
detect any strong and consistent effect after TGFβ, IL-4, and
IL-13 stimulation (Supplementary Figures 2A,B) as observed
for PDGF.
OTUD6B-AS1 Knockdown Reduces
Proliferation and Suppresses Apoptosis of
Dermal Fb
In order to further understand its function in the pathogenesis
of SSc, we knocked down OTUD6B-AS1 using ASO (33).
We used HC dermal Fb to mimic the downregulation
seen in the SSc patients and to recapitulate the extent
of OTUD6B-AS1 dysregulation effects in healthy cells.
Successful knockdown of OTUD6B-AS1 was confirmed
using qPCR at 48 and 72 h after transfection in HC dermal
Fb (Figure 3A). First, we looked at effects of OTUD6B-
AS1 knockdown on the expression of genes relevant for
key processes of fibrosis. However, we could not detect
significant differences in the gene expression of collagen 1α1
(COL1A1), fibronectin-1 (FN1) and alpha smooth muscle
actin (α-SMA) (Supplementary Figure 3). These data indicate
that OTUD6B-AS1 does not directly affect the expression of
fibrotic genes.
Proliferation and apoptosis are also important processes in
SSc pathogenesis (3). Thus, we assessed OTUD6B-AS1 function
on dermal Fb proliferation using the BrdU assay and real-
time monitoring of cell proliferation. Seventy-two hours after
OTUD6B-AS1 knockdown, we observed a minor reduction
in cell proliferation as detected by BrdU assay, however
there was no statistically significant difference (Figure 3B).
Real-time monitoring of cell proliferation showed that after
more than 75 h of OTUD6B-AS1 knockdown, dermal Fb
proliferated significantly slower than scrambled control treated
Fb (Figure 3C).
We also assess apoptosis after OTUD6B-AS1 knockdown
using Caspase 3/7 Glo assay R© and cleaved caspase 3WB analysis.
Caspase 3/7 activity was slightly, but significantly downregulated
72 h after OTUD6B-AS1 knockdown (Figure 3D). Moreover, the
ratio between cleaved and uncleaved caspase 3 was significantly
reduced 72 h after OTUD6B-AS1 knockdown in dermal Fb
(Figure 3E, Supplementary Figure 4A,B).
OTUD6B-AS1 Knockdown Reduces
Proliferation and Suppresses Apoptosis
in HPASMC
In the pathophysiology of SSc, cell cycle regulation, proliferation,
and resistance to apoptosis is particularly important for
the development of microvascular lesions, where vascular
smooth muscle cells strongly proliferate resulting in vessel
wall thickening and an occlusion of small arteries. The main
clinical manifestation is PAH (3–5, 34). Therefore, we also
performed OTUD6B-AS1 knockdown in HPASMC. OTUD6B-
AS1 expression was significantly reduced in HPASMC at 48 h
after transfection (Figure 4A, Supplementary Figure 4C–E).
We also assessed proliferation and apoptosis after knockdown
of OTUD6B-AS1 in HPASMC. HPASMC proliferation was
significantly reduced already 48 h after transfection as revealed
by BrdU assay (Figure 4B). Real-time monitoring of cell
proliferation confirmed that HPASMC showed reduced
proliferation earlier than dermal Fb and continued to proliferate
significantly slower than scrambled control treated cells
(Figure 4C). The apoptosis assay revealed that caspase
3/7 activity was significantly lower 48 h after OTUD6B-
AS1 knockdown (Figure 4D), and the ratio of cleaved and
uncleaved caspase 3 was significantly reduced 48 h after
knockdown (Figure 4E) similar as for dermal Fb. These
data suggest that OTUD6B-AS1 might be a regulator of
proliferation and apoptosis not only for dermal Fb, but also
for HPASMC.
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FIGURE 2 | Time course analysis of the expression of OTUD6B-AS1 and OTUD6B in SSc and HC dermal Fb after platelet-derived growth factor (PDGF) stimulation.
Dermal Fb were stimulated with PDGF (20 ng/ml) for 6, 24, 48, and 72 h. (A) Time course analysis of the expression of OTUD6B-AS1 and OTUD6B in SSc dermal Fb
after platelet-derived growth factor (PDGF) stimulation (n = 6). (B) Time course analysis of the expression of OTUD6B-AS1 and OTUD6B in HC dermal Fb after
platelet-derived growth factor (PDGF) stimulation (n = 5). Expression levels were measured by qPCR, normalized by GAPDH and RPLP0 and compared with
non-stimulated dermal Fb. Data are shown as single values. Statistical analysis was performed by one-way ANOVA with Dunnett’s multiple comparisons test.
OTUD6B-AS1 Knockdown Increases
CyclinD1 Expression in Dermal Fb
and HPASMC
Cyclins are among the most important cell proliferation
associated genes. They form active complexes with cyclin-
dependent kinases and regulates cell cycle progression
(35, 36).Thus, we analyzed the expression of the cell cycle
regulators Cyclin D1, Cyclin D2, and pro-proliferative
transcription factor MYC in dermal Fb after OTUD6B-AS1
knockdown. Cyclin D1 expression was significantly upregulated
at mRNA level and protein level, respectively, 48 and 72 h
after transfection (Figure 5A, Supplementary Figure 5). Cyclin
D2 and MYC expression was unchanged both at the mRNA
and protein level (Supplementary Figures 6A–D). We also
analyzed additional pro-fibrotic and/or proinflammatory
cytokines such as IL-6 and IGFBP3, and other cytokines
that act on Fb to promote fibrotic responses, such as
TGFB1 (37). However, after OTUD6B-AS1 knockdown
IL-6, TGFB1, and IGFBP3 expression was unchanged
(Supplementary Figure 7). Upregulation of Cyclin D1 was
confirmed in an independent set of experiments using
different two different anti-sense oligonucleotides targeting
OTUD6B-AS1 (Supplementary Figure 8A).
As observed in dermal Fb, Cyclin D1 expression was
significantly upregulated 48 h after OTUD6B-AS1 knockdown
at the mRNA and at the protein level in HPASMC (Figure 5B,
Supplementary Figure 8B). Cyclin D2 expression at the mRNA
level was slightly upregulated, while MYC expression was
unchanged (Supplementary Figure 9).
In addition, we analyzed the expression of the transcription
factor E2F1, which is located downstream of Cyclin D1 and has
been suggested as an apoptosis repressor in this context (38).
However, we could not detect a consistent upregulation of the
expression of E2F1, neither on the mRNA nor on the protein
level in dermal Fb (Supplementary Figures 10A,B). These data
suggest that OTUD6B-AS1 knockdown reduces cell proliferation
and suppresses apoptosis in dermal Fb likely independent
from E2F1.
Similarly, we did not detect any difference of E2F1 expression
at the mRNA level and protein level 48 h after transfection in
HPASMC (Supplementary Figures 10C,D).
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FIGURE 3 | OTUD6B-AS1 knockdown in dermal fibroblasts (Fb): effects on proliferation and apoptosis. HC dermal Fb were transfected with locked nucleic acid
antisense oligonucleotide (ASO) negative control or ASO targeting OTUD6B-AS1. (A) Efficacy of OTUD6B-AS1 knockdown 48 and 72 h after transfection in dermal Fb
was confirmed by qPCR (n = 5–6). (B) BrdU cell proliferation assay performed 72 h after transfection (n = 6). (C) Real-time monitoring of cell proliferation analysis. Cell
index (CI) was monitored every 5min from 0 to 13 h, every 15min from 13 to 25 h and every 30min from 25h until it reached plateau. CI was normalized at the time of
transfection. Slope analysis was performed by RTCA software 2.0 (ACEA Biosciences) (n = 6, representative picture is shown). (D) Caspase 3/7 assay performed 72 h
after transfection. Cells were treated by 1µM staurosporin (STP, Sigma) for a period of 16 h to induce apoptosis (n = 7). (E) Western blot analysis of uncleaved and
cleaved caspase 3 was performed 72 h after transfection. Cells were treated with 1µM staurosporin (STP, Sigma) for a period of 16 h to induce apoptosis. GAPDH
was used as a loading control. Densitometry analysis of cleaved caspase 3 was normalized to uncleaved caspase 3 (n = 4). Data are shown as single values and
mean. Statistical analysis was performed by paired t-test. k.d, knockdown.
All together, these results demonstrate that OTUD6B-AS1
targets Cyclin D1 and therefore it might be involved in cell
proliferation and cell cycle regulation.
OTUD6B-AS1 Knockdown Does Not Affect
OTUD6B Expression
Regulation of corresponding sense gene expression is the
most common mechanism of action of antisense transcripts
(12–14, 39). Therefore, we analyzed mRNA expression
and protein expression of OTUD6B after OTUD6B-AS1
knockdown. Total OTUD6B expression at the mRNA and
protein level was unchanged after OTUD6B-AS1 knockdown
in dermal Fb (Figure 6A, Supplementary Figure 8A and
Supplementary Figure 11A,B). Similarly, in HPASMC,
OTUD6B expression after OTUD6B-AS1 knockdown was
not changed (Figure 6B, Supplementary Figure 8B and
Supplementary Figure 11C,D).
During processing, lncRNAs are transported into the
cytoplasm or remain in the nucleus (8, 40) to exert their function.
Thus, the location of OTUD6B-AS1 can further give hints about
its mechanism of action. By using cell fractionation experiments,
we found that OTUD6B-AS1 was mainly localized in the nucleus
of dermal SSc Fb (Figure 6C).
Overall, these data indicate that OTUD6B-AS1 knockdown
does not affect expression of its sense gene OTUD6B in
dermal Fb and HPASMC. The effects on target gene
Cyclin D1, apoptosis, and proliferation are likely to
occur in the nucleus and might be due to OTUD6B-AS1
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FIGURE 4 | OTUD6B-AS1 knockdown in human pulmonary artery smooth muscle cells (HPASMC): effects on proliferation and apoptosis. HPASMC were transfected
with locked nucleic acid antisense oligonucleotide (ASO) negative control or ASO targeting OTUD6B-AS1. (A) Efficacy of OTUD6B-AS1 knockdown 48 h after
transfection in HPASMC was confirmed by qPCR. (B) BrdU cell proliferation assay performed 48 h after transfection (n = 6, biological replicates). (C) Real-time
monitoring of cell proliferation. Cell index (CI) was monitored every 5min from 0 to 13 h, every 15min from 13 to 25 h and every 30min from 25h until it reached
plateau. CI was normalized at the time of transfection. Slope analysis was performed by RTCA software 2.0 (ACEA Biosciences, n = 2, biological replicates, a
representative picture is shown). (D) Caspase 3/7 assay performed 48 h after transfection. Cells were treated by 1µM staurosporin for a period of 16 h to induce
apoptosis (n = 8, technical replicates). (E) Western blot analysis of uncleaved and cleaved caspase 3 was performed 48 h after transfection. Cells were treated with
1µM staurosporin (STP, Sigma) for a period of 16 h to induce apoptosis before cell collection. The same nitrocellulose membrane was used to detect uncleaved
caspase 3 and cleaved caspase 3 with different exposure time for detection. GAPDH was used as a loading control. Densitometry analysis of cleaved caspase 3 was
normalized to uncleaved caspase 3 (n=4, biological replicates). Data are shown as single values and mean. Statistical analysis was performed by paired t-test.
k.d, knockdown.
trans function rather than influencing OTUD6B sense
gene expression.
DISCUSSION
AS lncRNAs have been identified as crucial players in the
pathogenesis of different diseases such as cancer, however little
is known in fibrotic disorders including SSc. In this study, we
investigated the role of OTUD6B-AS1 in the pathogenesis of SSc.
First, our additional analyses on the expression pattern
showed that the downregulation of OTUD6B-AS1 and OTUD6B
mRNA was seen particularly in clinically involved, fibrotic skin
biopsies of SSc patients. This finding might give hints on their
pathophysiological role. However, the cohorts studied in these
experiments were rather limited in patient numbers and thus,
our findings should be confirmed in additional, larger cohorts.
In addition, due to the limited availability of protein from skin
biopsies, the downregulation of OTUD6B should be confirmed
by Western blots from biopsies of involved skin in additional
studies. We then analyzed the effects of pro-fibrotic and pro-
inflammatory cytokines on the expression of OTUD6B-AS1 and
OTUD6B. Pro-inflammatory cytokines are playing a major role
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FIGURE 5 | Cyclin D1 expression after OTUD6B-AS1 knockdown in dermal fibroblasts (Fb) or human pulmonary artery smooth muscle cells (HPASMC). HC dermal
Fb or HPASMC were transfected with locked nucleic acid antisense oligonucleotide (ASO) negative control or ASO targeting OTUD6B-AS1. (A) mRNA level of cyclin
D1 (CCND1) expression was measured 48 h after transfection (n = 6) and Cyclin D1 protein was measured 72 h after transfection (n = 6) in dermal Fb by Western
blot. (B) mRNA level of cyclin D1 (CCND1) expression (n = 8, biological replicates) and Cyclin D1 protein (n = 4, biological replicates) was measured 48 h after
transfection in HPASMC by Western blot. mRNA expression was normalized by GAPDH and RPLP0 and protein expression was normalized by GAPDH. Data are
shown as single values and mean. Statistical analysis was performed by paired t-test. k.d, knockdown.
in the pathogenesis of SSc, in particular in early, but also in later
stages of the disease (41). We could show that the expression
of OTUD6B-AS1 and OTUD6B was significantly downregulated
after PDGF simulation in dermal Fb. PDGF plays an important
role in fibrosis and regulation of inflammation. PDGFs are
primary mitogens and chemo-attractants for mesenchymal cells
and they are secreted from platelets, macrophages, fibroblasts,
and endothelial cells (1). PDGF and PDGF receptor β are highly
expressed in SSc skin (42). Activated microvascular pericytes
express more PDGFβ receptors in early SSc patients than normal
control or late-stage SSc patients (43). Transgenic mice with
constitutively activated PDGF receptor α develop multiple organ
fibrosis, including skin fibrosis (44). Our data indicated that
PDGF is an important regulator of OTUD6B-AS1 and OTUD6B
expression in dermal Fb.
In order to identify the functional role of OTUD6B-AS1,
we performed knockdown experiments of OTUD6B-AS1 using
ASO in HC dermal Fb and HPASMC. Dermal Fb from SSc
patients display increased proliferation in culture (45), and it
has been demonstrated that proliferation of vascular smooth
muscle cells is a key feature of the proliferative microangiopathy
characteristic for the vascular manifestations of SSc (46). Cyclin
D1 was identified as an OTUD6B-AS1 target in both dermal
Fb and HPASMC. Cyclin D1 is a well-characterized cell cycle
regulator and oncogene (36, 47, 48). Surprisingly, after OTUD6B-
AS1 knockdown, we observed increased cyclin D1 expression,
but reduced cell proliferation. Cyclin D1 expression levels are
subjected to change throughout the cell cycle. Specifically, a high
level of cyclin D1 expression is required for G1 phase. However,
cyclin D1 decreases during the S phase for efficient DNA
synthesis and increase again in G2 phase to continue proliferation
(49, 50). This phenomenon was observed in different cell
types including fibroblasts (50). Moreover, Cyclin D1 also has
an inhibitory function on DNA synthesis via binding with
proliferation cell nuclear antigen (PCNA) (51). Overexpression
of cyclin D1 in human Fb prevents DNA repair and prevents
cells from entering in S phase (52). This mechanism could
explain the reduction in proliferation that we observed in dermal
Fb and HPASMC after OTUD6B-AS1 knockdown. Thus, while
the OTUD6B-AS1 knockdown favored apoptosis resistance (see
below), which is supporting the pathogenesis of SSc, an inhibition
of proliferation would have to be interpreted as a compensatory
mechanisms. We did use HC cells for these experiments to better
mimic the downregulation found in SSc skin. In further studies,
these effects should be confirmed in primary SSc cells, to exclude
influence of SSc specific pathway alterations on our results.
We showed that OTUD6B-AS1 knockdown suppresses
apoptosis in dermal Fb and HPASMC. Fibrosis is a predominant
phenomenon in SSc. Fibrotic tissue is characterized by apoptosis
resistant myofibroblasts that arise from resident fibroblasts and
other cellular sources (3–5). The mechanisms of the resistance
to apoptosis are largely unknown. We have identified regulation
of cyclin D1 by OTUD6B-AS1 in dermal Fb as a possible novel
contributor to apoptosis resistance in SSc. Accordingly, it has
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FIGURE 6 | OTUD6B expression after OTUD6B-AS1 knockdown in dermal fibroblasts (Fb, A) or human pulmonary artery smooth muscle cells (HPASMC, B). HC
dermal Fb or HPASMC were transfected with locked nucleic acid antisense oligonucleotide (ASO) negative control or with ASO targeting OTUD6B-AS1. (A) mRNA of
total OTUD6B was measured 72 h after transfection (n = 5). OTUD6B protein was measured 72 h after transfection (n = 6) in dermal Fb by Western blot. (B) mRNA of
total OTUD6B was measured 48 h after transfection (n = 4, biological replicates). OTUD6B protein expression was measured 48 h after transfection by Western blot
(n = 4, biological replicates) in HPASMC. mRNA expression was normalized by GAPDH and RPLP0 and protein expression was normalized by GAPDH. (C) The
subcellular localization of OTUD6B-AS1 in SSc dermal Fb was analyzed by qPCR (n = 4). Expression levels were normalized by GAPDH and RPLP0. Data are shown
as single values and mean. Statistical analysis was performed by paired t-test. k.d, knockdown.
been reported that D-type cyclins (D1, D2, and D3) can repress
apoptosis in hematopoietic cells. Previous studies showed that
this effect of cyclins could bemediated via the transcription factor
E2F1, which in turn regulates the expression of Fas and Fas ligand
(38). However, we could not detect consistent changes in the
expression of E2F1 after knockdown of OTUD6B-AS1. With our
experimental set-up, we cannot completely exclude that there
are subtle changes of E2F1 and it downstream targets Fas and
Fas ligand at other time points, but other, E2F1 independent
mechanisms are much more likely. Knockdown of cyclin D1
could provide further insight into downstream targets mediating
the apoptosis resistance in SSc fibroblasts.
We also investigated the relationship between the expression
of OTUD6B-AS1 and sense gene OTUD6B. Our data showed
that PDGF stimulation downregulated the expression of both
OTUD6B-AS1 and OTUD6B, initially pointing to linked
mechanisms of action. However, while the majority of anti-sense
genes mediate their effects via direct interaction with the sense
gene, we did not detect any change of the expression of OTUD6B
on the RNA and protein level after OTUD6B-AS1 knockdown.
Recent investigations showed that in some circumstances, the
mature AS transcript does not influence sense gene expression
and the AS transcription itself is required for sense gene
expression (14, 53). This means, silencing AS transcript using
ASO does not necessarily affect sense gene expression. In our
experiments, we used ASO to reduce mature OTUD6B-AS1
levels and this might explain why OTUD6B expression was not
affected. On the other hand, our data suggest that OTUD6B-AS1
has an independent mechanism from its sense gene.
Taken together, we provide the first evidence for a functional
role of OTUD6B-AS1 in two cell types that play a major
role in SSc. We showed that the expression of OTUD6B-AS1
and OTUD6B was significantly downregulated in dermal Fb
after PDGF stimulation. OTUD6B-AS1 knockdown experiments
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revealed that OTUD6B-AS1 controls proliferation and apoptosis
of dermal Fb and HPASMC through the regulation of cyclin D1
expression. The OTUD6B-AS1 mode of action was independent
of its sense gene OTUD6B. These results suggest that OTUD6B-
AS1 downregulation might promote apoptosis resistance of
Fb and HPASMC contributing to cell dysregulation on the
pathophysiology of SSc.
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